NCT02154178

Fungal Biomarkers to Reduce Duration of Empirical Antifungal Therapy: a Randomized Comparative Study (STAFE)

Fungal Biomarkers to Reduce Duration of Empirical Antifungal Therapy: a Randomized Comparative Study

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 110 (actual)
• Sponsor: University Hospital, Lille · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The investigators hypothesized that the use of biomarkers of invasive fungal infections would increase the percentage of early discontinuation of empirical antifungal therapy and thus reduce the duration of treatment in ICU patients.

Detailed description

The duration of empirical/preemptive anti fungal treatment will be based in the intervention group on biomarker results. Biomarkers of fungal disease will performed before starting anti fungal treatment and at day 4.

Conditions

• Fungal Infection
• Critical Illness

Interventions

Type	Name	Description
OTHER	Biomarker group	use of invasive fungal disease biomarkers (β-1,3-glucan, mannan/anti-mannan antibodies)

Timeline

• Start date: 2014-07-01
• Primary completion: 2016-10-01
• Completion: 2016-12-01
• First posted: 2014-06-03
• Last updated: 2025-12-22

Locations

1 site across 1 country: France